Quarterly report · Q1
4564.TEDINET S100OW16
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥386m | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥93m | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥307m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥314m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥277m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥2.0bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.6bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥373m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-1.44 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.6% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥101m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥215m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | −¥206m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥107m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥96m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥87m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥33m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥62,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥431m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥93m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | −¥464m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 313
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -33193000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -464449000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -107068000 | JPY |
| Operating income | Prior1YTDDuration | -571517000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 5610000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 380093000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 385703000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 385703000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 55000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 55000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -55000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 5665000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 380093000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 385759000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -55000 | JPY |
| Net sales | CurrentYTDDuration | 385703000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -215473000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 9271000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -206202000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -101150000 | JPY |
| Operating income | CurrentYTDDuration | -307352000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第22期第１四半期（自 2022年４月１日 至 2022年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | OncoTherapy Science, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 嶋田 順一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市高津区坂戸三丁目２番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044－820－8251 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)管理本部長 二之宮 修 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市高津区坂戸三丁目２番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044－820－8251 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)管理本部長 二之宮 修 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05363 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45640 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Filer name in english | FilingDateInstant | OncoTherapy Science, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |